TRAWS PHARMA INC (TRAW) Stock Fundamental Analysis

NASDAQ:TRAW • US68232V8845

1.61 USD
+0.04 (+2.55%)
At close: Feb 20, 2026
1.64 USD
+0.03 (+1.86%)
After Hours: 2/20/2026, 8:07:57 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, TRAW scores 4 out of 10 in our fundamental rating. TRAW was compared to 193 industry peers in the Pharmaceuticals industry. TRAW scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TRAW has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year TRAW was profitable.
  • In the past year TRAW has reported a negative cash flow from operations.
  • In the past 5 years TRAW always reported negative net income.
  • TRAW had a negative operating cash flow in each of the past 5 years.
TRAW Yearly Net Income VS EBIT VS OCF VS FCFTRAW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of TRAW (750.81%) is better than 100.00% of its industry peers.
  • TRAW's Return On Equity of 2055.51% is amongst the best of the industry. TRAW outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 750.81%
ROE 2055.51%
ROIC N/A
ROA(3y)-116.91%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRAW Yearly ROA, ROE, ROICTRAW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • TRAW has a Profit Margin of 3282.61%. This is amongst the best in the industry. TRAW outperforms 100.00% of its industry peers.
  • The Operating Margin and Gross Margin are not available for TRAW so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 3282.61%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRAW Yearly Profit, Operating, Gross MarginsTRAW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TRAW has more shares outstanding
  • There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRAW Yearly Shares OutstandingTRAW Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M
TRAW Yearly Total Debt VS Total AssetsTRAW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -73.98, we must say that TRAW is in the distress zone and has some risk of bankruptcy.
  • TRAW has a worse Altman-Z score (-73.98) than 93.23% of its industry peers.
  • There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -73.98
ROIC/WACCN/A
WACC9.26%
TRAW Yearly LT Debt VS Equity VS FCFTRAW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 1.22 indicates that TRAW should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.22, TRAW is doing worse than 78.65% of the companies in the same industry.
  • TRAW has a Quick Ratio of 1.22. This is a normal value and indicates that TRAW is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.22, TRAW is doing worse than 71.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 1.22
TRAW Yearly Current Assets VS Current LiabilitesTRAW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • TRAW shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 119.99%, which is quite impressive.
  • TRAW shows a strong growth in Revenue. In the last year, the Revenue has grown by 1159.29%.
EPS 1Y (TTM)119.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.1%
Revenue 1Y (TTM)1159.29%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.82% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, TRAW will show a very strong growth in Revenue. The Revenue will grow by 267.27% on average per year.
EPS Next Y99.97%
EPS Next 2Y40.89%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue Next Year1117.39%
Revenue Next 2Y-41.42%
Revenue Next 3Y384.76%
Revenue Next 5Y267.27%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TRAW Yearly Revenue VS EstimatesTRAW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
TRAW Yearly EPS VS EstimatesTRAW Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -20K -40K -60K -80K

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 0.06, the valuation of TRAW can be described as very cheap.
  • Based on the Price/Earnings ratio, TRAW is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • TRAW's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.99.
  • TRAW is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.06
Fwd PE N/A
TRAW Price Earnings VS Forward Price EarningsTRAW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRAW Per share dataTRAW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • TRAW's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • TRAW's earnings are expected to grow with 25.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y40.89%
EPS Next 3Y25.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TRAW!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRAWS PHARMA INC

NASDAQ:TRAW (2/20/2026, 8:07:57 PM)

After market: 1.64 +0.03 (+1.86%)

1.61

+0.04 (+2.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners16.14%
Inst Owner Change158.27%
Ins Owners6.95%
Ins Owner Change4.88%
Market Cap12.86M
Revenue(TTM)2.85M
Net Income(TTM)93.42M
Analysts82.86
Price Target8.16 (406.83%)
Short Float %8.9%
Short Ratio1.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2132.84%
Min Revenue beat(2)-100%
Max Revenue beat(2)4365.69%
Revenue beat(4)1
Avg Revenue beat(4)1064.22%
Min Revenue beat(4)-100%
Max Revenue beat(4)4365.69%
Revenue beat(8)1
Avg Revenue beat(8)527.74%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)80.02%
EPS NY rev (1m)0%
EPS NY rev (3m)99.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1117.39%
Valuation
Industry RankSector Rank
PE 0.06
Fwd PE N/A
P/S 4.52
P/FCF N/A
P/OCF N/A
P/B 2.83
P/tB 6.52
EV/EBITDA N/A
EPS(TTM)28.26
EY1755.28%
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0.36
BVpS0.57
TBVpS0.25
PEG (NY)0
PEG (5Y)N/A
Graham Number19.02
Profitability
Industry RankSector Rank
ROA 750.81%
ROE 2055.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3282.61%
GM N/A
FCFM N/A
ROA(3y)-116.91%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.22
Quick Ratio 1.22
Altman-Z -73.98
F-Score6
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.1%
EPS Next Y99.97%
EPS Next 2Y40.89%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue 1Y (TTM)1159.29%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year1117.39%
Revenue Next 2Y-41.42%
Revenue Next 3Y384.76%
Revenue Next 5Y267.27%
EBIT growth 1Y34.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-66.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.14%
OCF growth 3YN/A
OCF growth 5YN/A

TRAWS PHARMA INC / TRAW FAQ

What is the fundamental rating for TRAW stock?

ChartMill assigns a fundamental rating of 4 / 10 to TRAW.


What is the valuation status for TRAW stock?

ChartMill assigns a valuation rating of 4 / 10 to TRAWS PHARMA INC (TRAW). This can be considered as Fairly Valued.


How profitable is TRAWS PHARMA INC (TRAW) stock?

TRAWS PHARMA INC (TRAW) has a profitability rating of 3 / 10.


What is the valuation of TRAWS PHARMA INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TRAWS PHARMA INC (TRAW) is 0.06 and the Price/Book (PB) ratio is 2.83.


What is the expected EPS growth for TRAWS PHARMA INC (TRAW) stock?

The Earnings per Share (EPS) of TRAWS PHARMA INC (TRAW) is expected to grow by 99.97% in the next year.